Core Viewpoint - MBX Biosciences has completed the last subject's visit in its Phase 1 trial of MBX 1416, a long-acting GLP-1 receptor antagonist aimed at treating post-bariatric hypoglycemia (PBH), marking a significant milestone in the program [1][2] Group 1: Clinical Trial Details - The Phase 1 trial is a randomized, double-blind, placebo-controlled study involving 69 healthy adult participants, focusing on safety, tolerability, pharmacokinetics, and pharmacodynamics of MBX 1416 [2] - The primary endpoint of the trial is safety and tolerability, while secondary endpoints include pharmacokinetics and pharmacodynamics [2] - Full topline results from the trial are expected to be shared in early January 2025 [2] Group 2: Product Information - MBX 1416 is designed to prevent severe hypoglycemia in individuals with PBH, utilizing the proprietary PEP™ platform developed by the company [3] - The product aims to improve the quality of life for patients suffering from PBH, a condition with no approved therapies to date [3][4] Group 3: Market Context - Post-bariatric hypoglycemia is a serious complication following bariatric surgery, characterized by recurrent hypoglycemic episodes, which can significantly impact daily activities and quality of life [4] - As the prevalence of bariatric surgeries increases, the incidence of PBH is expected to rise, highlighting the urgent need for effective treatments [4] Group 4: Company Overview - MBX Biosciences focuses on developing novel precision peptide therapies for endocrine and metabolic disorders, with a pipeline that includes MBX 2109 for chronic hypoparathyroidism and an obesity portfolio [5] - The company leverages its proprietary PEP™ platform to enhance the efficacy and safety of peptide therapies, aiming to address significant unmet medical needs [6]
MBX Biosciences Announces Last Subject Last Visit in Phase 1 Trial of MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia